The gene transfer of tumor -specific chimeric immunoglobulin T -cell receptors ( cIgTCRs ) combining antibody -like specificity with the effector cell function could be an attractive tool in immunotherapy. In this study, we directed the human natural killer ( NK ) cell line YT to tumor cells by gene transfer of a cIgTCR with specificity against the human carcinoembryonic antigen ( CEA ). The cIgTCR was constructed of a CEA -specific humanized single -chain Fv antibody fragment fused to the IgG1 Fc domain and the CD3 chain. YT cells were transfected with the cIgTCR gene by electroporation and cIgTCR -expressing cells were enriched by immunoaffinity purification. cIgTCR -expressing YT cells specifically lysed CEA + colon carcinoma cell lines, which were resistant to the parental YT cell line. The lysis was not inhibited in the presence of soluble CEA. Receptor gene -modified YT cells retained their CEA -specific cytolytic activity after -irradiation in vitro and inhibited the tumor growth in vivo after adoptive transfer into NOD / SCID mice. This gene -modified NK cell line available in unlimited source might be useful in clinical immunotherapy of CEA + cancer.
T he failure of the immune system to generate sufficient tumor-directed immune cells in tumor patients could be overcome by the adoptive transfer of tumor-specific cytotoxic lymphocytes. An adoptive immunotherapy is dependent on the availability, the specificity and the antitumor properties of the transferred effector cells.
Recently, strategies based on the genetic modification of T cells using recombinant T-cell receptor (TCR ) genes 1 have been developed. Immunoglobulin -based chimeric T-cell receptors (cIgTCRs ), also called ''T bodies'', 2 are from particular interest. They consist of a single-chain Fv (scFv ) fragment derived from the variable ( V ) domains of the light (V L ) and heavy chain ( V H ) of monoclonal antibodies ( mAb ) joined by a flexible peptide linker 3, 4 fused to a signal-transducing chain like the chain of the Fc"RI receptor or the CD3 chain; thus, they combine the specificity of an antibody -based MHC -unrestricted recognition with the T-cell function. 2, 5 The development of efficient retroviral gene delivery systems for activated primary T cells and tumor-infiltrating lymphocytes ( TILs ) 6, 7 permitted the possibility to generate large numbers of virus - 8 or tumor-specific T cells. 9 -13 Another strategy could be the use of natural killer (NK ) cells, which do not express individual antigen specific receptors unlike T cells. Their cytolytic activity is regulated by activatory and inhibitory NK cell receptors.
14, 15 The usage of NK cells has been tested for adoptive immunotherapy. 16, 17 According to shared signal mechanisms with T cells, NK cells could be directed to tumor cells by gene transfer with chimeric receptor genes containing the chain. 18, 19 The transfection of primary NK cells has not been described but some groups introduced the interleukin -2 ( IL -2 ) gene into human NK cell lines. 20, 21 Other groups demonstrated the CD18 gene transfer into mutant YT-1 cells 22 or the retroviral transduction of a chimeric chain gene into the NK3.3 clone. 19 In this report, we describe the targeting of the human NK cell line YT 23 by gene transfer of a tumor-specific cIgTCR. The YT cell line comprises the advantage of cytokine -independent growth 23 and is transfectable by electroporation. 22 We constructed a cIgTCR specific for the carcinoembryonic antigen ( CEA ). CEA is expressed in a number of tumors of epithelial origin such as colorectal, gastric and pancreatic carcinomas, lung and endometrial adenocarcinoma, and mucious ovarian carcinoma. 24 The scFv fragment was constructed of the V regions of the CEAspecific humanized mAb BW431 /26, 25, 26 which has been successfully used for radioimmunodiagnostics in patients. 27 -29 The human IgG1 Fc domain served as spacer between the scFv fragment and the CD3 signal chain, which can be necessary for an efficient receptor function. 10, 12, 30 The Fc part also promotes the homodimerization of the cIgTCR chains 11 and their plasma membrane expression. 7 Furthermore, we examined the cytotoxic properties of the cIgTCR gene -transfected YT cell line against CEA + tumor cell lines. To discuss its use for an adoptive immunotherapy, we also investigated the cytotoxicity of -irradiated cIgTCR -expressing YT cells in vitro and in vivo.
Materials and methods

Cell lines
The human NK cell line YT was kindly provided by J Yodoi ( Institute for Virus Research, Kyoto, Japan ). 23 YT cells were cultured with RPMI-1640 supplemented with 10% (vol / vol ) heat -inactivated fetal calf serum ( FCS ) and 50 g/mL gentamicin (all from Gibco BRL , Karlsruhe, Germany) with a maximum concentration of 2.5Â10 5 cells / mL. 32 (kindly provided by J Schlom, National Cancer Institute, NIH, Bethesda, MD ) were cultured in DMEM ( Gibco BRL ) supplemented with 10% (vol /vol ) FCS and 50 g /mL gentamicin. The MC32A cell line was cloned by limited dilution.
Construction of the scFv fragments
The CEA -specific scFv antibody fragment was constructed of the humanized mAb BW431 /26. 25 The plasmids containing the cDNA of the BW431 /26 V regions were kindly provided by K Bosslet (Behringwerke, Marburg, Germany ). The V L region was amplified from pUC19 -LC431 by polymerase chain reaction (PCR ) using primer BW431-V L -1A (5 0 -CGAGTCTAGA ACCATGGACA TCCAGATGACC-3 0 ) and BW431 -V L -2 (5 0 -CACCAC-TCCC GGGCTTTCCT GAACCGGAAG TGGATCC-TTT GATTTC CACC TTGGTCCCTT G -3 0 ) and the V H region was amplified from pAB -431/ 26-V H -humÁ3 25, 26 using primer BW431 -V H -1 (5 0 -AAGCCCGGGA GTG-GTGAAGG TAGCACTAAA GGCCAGGTCC AGCTG-CAGGA GAGC-3 0 ) and BW431-V H -2 ( 5 0 -TTGGATCCGG CCGCACCTGA GGAGACGGTG ACCGT-3 0 ). The V L fragment digested with NcoI and SmaI and the V H fragment digested with SmaI and NotI (restriction enzymes from New England Biolabs, Frankfurt am Main, Germany ) were cloned into the NcoI and NotI sites of the E. coli periplasmatic expression vector pOPE51 33 (kindly provided by S Dübel, Molecular Genetics, University Heidelberg, Germany ) to obtain the scFv scBW431/26 consisting of the N terminal V L region followed by the Linker-218 ( -GSTSGSGKPGSGEGSTKG -) 4 and the V H region (pOPE51 -scBW431 /26).
An scFv antibody fragment specific for the hapten 2-phenyloxazoline -5-one (phOx ), which was isolated from a human phage antibody library and improved by chain shuffling 34 was redesigned with the Linker-218 connecting the V L and V H domains analogously to scBW431 / 26. Briefly, plasmids pOPE51 -scBW431 / 26 and pOPE51 -phOx were digested with Eco81I (Fermentas, St. LeonRot, Germany ) and PvuII. The V H domain of scBW431 / 26 was substituted by the V H domain of the phOx -specific scFv. Finally, the BW431 /26 -V L domain was substituted using the restriction sites NcoI and NotI with the V L domain of the phOx -specific scFv obtained by PCR from pOPE51 -phOx using primer phOx -V L -1 (5 0 -AGAAC-CATGG ACATCCAGAT GACGCAGCCG CCCTCA -3 0 ) and phOx -V L -2 (5 0 -AGAAGGATCC TAGGACGGTG ACCTTGGTC -3 0 ) (pOPE51-scPhOx ).
Construction of the scFv -hFc fusion proteins
The hFc fragment consisting of the IgG1 heavy -chain hinge -CH 2 -CH 3 domains ( according to swissprot P01-857) 35 was obtained from the plasmid pCMX -sFGFR4 -hFc 36 (kindly provided by M Seidensticker, MDC) using primer hFc -1 ( 5 0 -CAAGAAGCTT AGCAAGATCT GCG-GCCGCCG AGCCCAAATC TTGTGACA -3 0 ) and hFc -2 (5 0 -CAACTCTAGA CTCGAGACGC TCATTTACCC GG-AGACA -3 0 ). The hFc fragment was cloned into the HindIII and XbaI sites of pCMX ( pCMX -hFc). The secretory leader of the human IgG1 light-chain gene 37 was constructed by PCR using the oligonucleotides Leader-1 (5 0 -GATGA-AGCTT AGCAGATCTC CATGGGATGG AGCTGTATCA TCCTCTTCCT GGTAGC -3 0 ) and Leader-2 ( 5 0 -GTAGA-GTACT GTGCACGCCT GTAGCTGTTG CTACCAGGAA GAGGATGATA C -3 0 ) as template and primer. The obtained leader fragment was digested with HindIII and ScaI. The plasmids pOPE51 -scBW431 /26 and pOPE51 -scPhOx were digested with NcoI followed by a removal of the 5 0 overhangs by incubation with S1 -nuclease ( Roche Diagnostics, Mannheim, Germany ). Finally, the scFv fragment cDNAs were obtained by digestion with NotI and cloned with the leader fragment into the HindIII and NotI sites of pCMX -hFc. The obtained plasmids were designated as pCMX -scBW431 / 26-hFc and pCMX -scPhOx -hFc.
Calcium phosphate transfection of 293T cells
One day before transfection 2Â10 5 293T cells/well were seeded into six -well plates (TPP, Trasadingen, Switzerland). Two micrograms of the plasmids pCMX -scBW431 / 26-hFc or pCMX -scPhOx-hFc were diluted in 125 L 250 mM CaCl 2 . The same volume of 2xHeBSP ( 10 
Deisenhofen, Germany ] adjusted to pH 6.95) was added dropwise to the DNA solution and mixed several times. After 15 minutes incubation at room temperature the precipitate was added to the cells. The cells were incubated with the DNA calcium phosphate precipitate overnight at 378C and 5% ( vol /vol ) CO 2 before the medium was exchanged. The supernatants containing the scFv -hFc fusion proteins were harvested after 3 days.
ELISA CEA (2 g/mL; Calbiochem, Bad Soden, Germany ), phOx -labeled bovine serum albumin ( phOx -BSA ) kindly provided by J Schenk (MDC ) or BSA (Sigma ) were coated in 50 L 50 mM bicarbonate buffer ( pH 9.6) per well onto
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-well Maxisorb
2 microtiter plates ( Nunc, Wiesbaden, Germany ) overnight at room temperature. The wells were blocked using 2.5% ( wt/ vol ) hydrolyzed caseinate (Serva ) in PBS. Supernatant of 293 T cells (100 L /well) expressing scBW431/26-hFc or scPhOx-hFc were incubated for 1 hour at room temperature. Horseradish peroxidase -conjugated goat anti -human -IgG -Fc F( ab 0 ) 2 (50 L /well; Dianova, Hamburg, Germany ) was used diluted 1:1000 in blocking buffer as secondary antibody and incubated for 1 hour at room temperature. The enzyme reaction was performed using 100 L /well 2 mg / mL o -phenyldiamine (Sigma ) in citrate -phosphate buffer (10 g /L citric acid, 14 g /L Na 2 HPO 4 [Serva ], pH5.0; add 20 L 30% H 2 O 2 [ Sigma ] per 100 mL before use ). The reaction was stopped by adding 50 L / well 3 N NaOH ( Roth, Karlsruhe, Germany ). The extinction was measured at 492 nm.
Isolation of the CD3 chain cDNA
The cDNA of the CD3 chain was isolated from activated peripheral blood lymphocytes ( PBLs ). PBLs were prepared from freshly drawn heparinized blood of healthy donors. Briefly, peripheral mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Lymphoprep
2
( 1,077 g /mL, Nycomed, Roskilde, Denmark ) for 30 minutes at 600Âg and 208C. Thrombocytes were depleted from the PBMC fraction by density gradient centrifugation using Optiprep 2 ( Nycomed ) adjusted to 1.063 g /mL with Ultrasaline A ( Biowhittaker, Verviers, Belgium ) for 15 minutes at 350Âg and 208C and by two to three additional washing steps using plain RPMI -1640. PBLs were obtained by adherence of the monocytes to plastic in Iscove's modified Dulbecco's medium ( IMDM, Gibco BRL, Karlsruhe, Germany ) supplemented with 10% (vol / vol ) pooled heatinactivated human AB serum (Biowhittaker ) overnight. The nonadherent PBLs were washed and 10 6 cells/mL were activated 1 week in RPMI-1640 containing 10% (vol / vol ) human AB serum, 50 g/mL gentamicin, and 1 g/mL phytohemagglutinin ( Sigma).
Total RNA was prepared from the activated PBL using the TRIzol Reagent 2 (Gibco BRL, Karlsruhe, Germany ) according to the supplier's description. The poly -(A + )-mRNA was isolated from total RNA using oligo -( dT )-cellulose ( Sigma ) and transcribed into cDNA using the Universal RiboClone 1 cDNA -Synthese system (Promega, Mannheim, Germany ). The cDNA of the CD3 chain was isolated from the cDNA of activated PBL by PCR using the primer -1A (5 0 -GGACAAGATG AAGTGGAAGG -3 0 ) and -2A (5 0 -CGTGAGAAGA GTGAACCGGG -3 0 ) and the T /A -cloning system (Invitrogen, Karlsruhe, Germany ). The fragment containing the transmembrane and the cytoplasmic domain of the chain was amplified from the cDNA using the primer -1B (5 0 -CCTAGGATCC CAAACTCTGC TACCTGCTGG ATGGAATCC -3 0 ) and -2B (5 0 -CCAGAAGCTT TGAGTGGAGA AATCCCC-TGG CAGTTAGCGA CC -3 0 ).
Construction of the cIgTCRs
A BamHI site was inserted into the C terminus of the hFc fragment by PCR using the plasmid pCMX -sFGFR4 -hFc and the primers hFc -1 ( see above ) and hFc -2B (5 0 -TAACCTCGAG TCTAGATCAT GGATCCTTAC CCGG-AGACAG GGAGA -3 0 ). The obtained hFcB PCR fragment was cloned into the HindIII and XhoI sites of the mammalian expression vector pCDNA3 (Invitrogen ). The transmembrane and cytoplasmatic fragment of the chain was fused to the BamHI site of the hFcB fragment to obtain the plasmid pCDNA3 -hFc. The fragments consisting of the leader sequence and the scFv fragments from pCMX -scBW431 / 26-hFc or pCMX -scPhOx -hFc were cloned into the HindIII and NotI sites of pCDNA3 -hFc. The plasmids containing the CEA -specific cIgTCR scBW431 /26 -hFc and the phOx -specific cIgTCR scPhOx -hFc were designated as pCDNA3 -scBW431 /26 -hFc and pCDNA3 -scPhOxhFc, respectively.
Gene transfer of the cIgTCR constructs into the human NK cell line YT
The plasmids pCDNA3 -scBW431 /26 -hFc or pCDNA3 -scPhOx -hFc were transfected by electroporation into the YT cell line. Briefly, 10 7 YT cell were washed and resuspended with plain RPMI -1640. The cells were transferred into 0.4-cm electroporation cuvettes ( Eurogentec, Cologne, Germany ) and 20 g of the plasmid DNA was added. The cells were pulsed with 250 V and 975 F using the GenePulser 2 II with Capacitance Extender 2 II (BioRad, Munich, Germany ). The selection of the transfected YT cells was started 48 hours after electroporation by adding 250 g/ mL G418 ( Calbiochem ) to the culture medium. After 1 week selection dead YT cells were removed by density gradient centrifugation using Lymphoprep 2 for 15 minutes at 600Âg and 208C.
Immunoaffinity purification of cIgTCR -expressing YT cells
The cIgTCR -expressing YT cells were sorted after selection with G418 using a FACSCalibur 2 high performance cell sorter ( Becton Dickinson, Bedford, MA ). Briefly, 10 7 of the transfected YT cells were stained with 500 L FITCconjugated goat anti -human -IgG -Fc F( ab 0 ) 2 fragment ( Dianova ) 1:100 diluted in sterile PBS supplemented with 0.5% (wt/ vol ) BSA ( Sigma) and 2 mM EDTA (Serva ). The enrichment of cIgTCR -expressing YT cells was repeated after 1-2 weeks. Alternatively, cIgTCR -expressing cells could be additionally stained with anti -FITC MicroBeads and sorted using the magnetic cell -sorting system MACS 2 following the supplier's description (Miltenyi Biotec, Bergisch Gladbach, Germany ).
FACS analysis
The expression of the cIgTCR was detected using 1:100 diluted FITC -conjugated goat anti -human -IgG -Fc F( ab 0 ) 2 fragment (Dianova ). A total of 5Â10 5 cells were stained in PBS, 0.5% (wt /vol ) BSA, and 0.1% ( wt /vol ) NaN 3 (Sigma ) for 15 minutes at 48C. Propidium iodide (PI, Sigma ) was added with a final concentration of 1 g/mL to the stained cells. The FACS measurement was performed using a FACSort 2 (Becton Dickinson ). Mock (pCDNA3 ) transfected YT cells were used as negative control. The CEA expression of the target cell lines was analyzed using the
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Tumor targeting of a human NK cell line T Schirrmann and G Pecher scBW431/26-hFc protein containing supernatant followed by an FITC -conjugated goat anti -human -IgG -Fc F( ab 0 ) 2 fragment. The scPhOx -hFc protein was used as control. Additionally, the colon carcinoma cell lines were analyzed using the anti -CEA mAb CEJ065 (Beckman Coulter, Unterschleissheim -Lohhof, Germany ) and an appropriate isotype control mAb followed by an FITC -conjugated goat anti -mouse -IgG( H +L ) F(ab 0 ) 2 fragment ( Dianova ). CEJ065 cross -reacts with NCA (nonspecific cross -reacting antigen) according to the supplier's description.
Cytotoxicity assay
The cytotoxicity was examined with standard 6 -hour 51 Crrelease assays. Briefly, target cell lines MC38, MC32A, SW480, SW948, SW1222, LoVo, and LS174T were labeled using [
51 Cr ]sodium chromate (Dupont NEN, Bad Homburg, Germany ). The labeled target cells were washed at least thrice with RPMI-1640 supplemented with 10% (vol / vol ) FCS. cIgTCR and mock transfected YT cells were used as effector cells in this assay. A total of 1.5Â10 5 effector cells and 3Â10 3 51 Cr-labeled target cells per well were plated into V-bottom 96-well plates (Greiner, Frickenhausen, Germany ) using IMDM supplemented with 10% (vol /vol ) FCS corresponding to an effector to target ( E:T ) ratio of 25:1. Further E:T ratios were performed by half dilution of the effector cells. Spontaneous and maximum 51 Cr release were determined by incubating target cells in medium or in 1% (vol /vol ) Triton -X100 ( Sigma ), respectively. All samples were performed at least in triplicate. Plates were centrifuged for 5 minutes at 200Âg and incubated for 6 hours at 378C and 5% CO 2 . After incubation the plates were carefully shaken for 5 minutes and centrifuged for 5 minutes at 300Âg. Fifty microliters supernatant per well were transferred to 96-well Lumaplates.
2 Dried and sealed plates were measured using the -scintillation counter Topcount 2 (Packard Bioscience, Dreieich, Germany ). The percent lysis was calculated with following formula: lysis ð%Þ ¼ lysis ðcounts per minute; cpmÞÀspontaneous lysis ðcpmÞ 100% lysis ðcpmÞÀspontaneous lysis ðcpmÞ Â100%
Soluble CEA inhibition assay
The cytotoxicity of scBW431 / 26-hFc -expressing YT cells was examined against MC32A cells performing a 51 Cr-release assay after addition of soluble CEA protein with a final concentration of 0, 100 ng/mL, 1 g/mL, or 10 g /mL to the medium.
-Irradiation of YT cells
The (1 -4 )Â10 7 scBW431 /26 -hFc -expressing YT cells for each attempt were centrifuged at 200Âg and 48C. The cell pellets were placed on ice and irradiated with 0, 2000, 5000, 7500, or 15000 rad using a 137 Cs -radiation source. The irradiated cells were cultured for 16 hours in culture medium without G418. The cytotoxicity of the irradiated scBW431 / 26-hFc YT cells were tested against CEA + MC32A tumor cells performing 51 Cr-release assays. scBW431 / 26-hFc YT cells treated with 5000 rad were also analyzed 3 and 5 days after -irradiation. The viability of YT cells after irradiation was examined by trypan blue ( Sigma) exclusion.
NOD / SCID mouse tumor model
Male NOD /SCID mice were held under standardized pathogen -free conditions at EPO, Berlin, Germany. All animal experiments were performed under the auspices of the German Animal Protection Law. Three groups with six mice per group were subcutaneously injected with 10 6 MC32A cells together with 10 7 -irradiated (5000 rad ) YTpCDNA3 -scBW431 /26 -hFc, 10 7 -irradiated (5000 rad ) YT-pCDNA3-scPhOx-hFc, or PBS. Tumor diameters were measured twice per week with a caliper and tumor volumes were calculated according to the formula: ( aÂb)Â0.5 cm ( where a represents the largest and b the smallest diameter ). Mice were sacrificed when the tumor volume exceeded 10% of the body weight (>1 cm 3 ). Curves were compared using the Mann -Whitney U test.
Results
scBW431 / 26 -hFc protein binds specifically to CEA
To analyze the antigen specificity of the cIgTCRs, the extracellular part was expressed as scFv -hFc protein (Fig  1a) in 293 T cells. The secretory leader sequence enabled the extracellular expression and the analysis of the scFv -hFc protein directly from the supernatant of pCMX -scBW431 / 26-hFc-or pCMX -scPhOx -hFc -transfected 293T cells. 
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The scBW431 /26 -hFc protein bound specifically to CEA but not to BSA -coated wells as determined using ELISA ( Fig 2a) . The scPhOx -hFc protein bound specifically to phOx -BSA (Fig 2b) .
cIgTCR gene transfer into the YT cell line
The plasmids pCDNA3-scBW431 /26 -hFc or pCDNA3-scPhOx -hFc containing cIgTCR constructs (Fig 1b ) were successfully transfected into the YT cell line by electroporation with a mean transfection efficiency of 2% as determined by flow cytometry. After selection with G418 cIgTCR -expressing YT cells were successfully enriched by immunoaffinity purification against the human Fc domain of the receptor using FACS or MACS.
2 After two times enrichment 90% of the transfected YT cells expressed the cIgTCR on their surface ( Fig 3) . It should be noted that biotinylated goat anti -human -IgG -Fc antibody and MicroBead -conjugated streptavidin could not be used for the enrichment of the cIgTCR -expressing YT cells. Strong cross -linking probably leads to mutual lysis of the enriched receptor expressing YT cells.
scBW431 / 26 -hFc protein binds to CEA + colon carcinoma cell lines
The expression of the cIgTCR antigens on colon carcinoma cell lines was evaluated by flow cytometry using the scBW431/26-hFc and scPhOx -hFc proteins, respectively ( Fig 4 ) . The whole population of CEA transgenic MC32A cells was stained with scBW431 / 26-hFc protein similar to the mAb CEJ065 whereas CEA À MC38 cells were not stained, neither with scBW431 / 26-hFc protein nor with CEJ065. The human colon carcinoma cell lines LoVo, LS174T, SW948, and SW1222 were stained with scBW431 / 26-hFc protein but to a lower percentage than with the mAb CEJ065. SW480 cells were negative for the staining with the scBW431 / 26-hFc protein and the mAb CEJ065. The phOxspecific scPhOx -hFc protein did not bind to any of the analyzed tumor cell lines and was used as negative control for the scBW431 / 26-hFc protein.
CEA -directed cytotoxicity of scBW431 / 26 -hFcexpressing YT cells
The cytolytic activity of the cIgTCR -expressing YT cells was examined using 6 -hour 51 Cr-release assays against CEA + and CEA À colon carcinoma cell lines. YT cells expressing the CEA -specific cIgTCR scBW431 /26 -hFc lysed the CEA + transgenic MC32A cells up to 50% (Fig 5a ) . The lysis was also efficient at low E:T ratios. The CEA À MC38 cells were not lysed by the scBW431 / 26-hFc gene -transfected YT cells (Fig 5b ) . scBW431 / 26-hFc -expressing YT cells lysed human colon carcinoma cell lines LoVo, LS174T, SW948, and SW1222 up to 15% ( Fig 5c, d, f, g ). The cell line SW480 was not lysed by scBW431 / 26-hFc -transfected YT cells (Fig 5e) . Mock transfected YT cells or YT cells transfected with the phOx -specific cIgTCR used as control effector cells did not lyse any of the used colon carcinoma cell lines. ( Fig 5h) . scPhOx -hFc protein were tested for their antigen binding against ( a ) CEA or ( b ) phOx -BSA using ELISA. These supernatants were also analyzed against BSA. Supernatant of mock transfected 293 T cells was used as control.
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Tumor targeting of a human NK cell line T Schirrmann and G Pecher Figure 4 FACS analysis of the CEA expression on colon carcinoma cell lines. The cell line MC38 ( a, b ) and its CEA transgenic derivative MC32A ( c, d ) and the human colon carcinoma cell lines LoVo ( e, f ), LS174T ( g, h ), SW480 ( i, j ), SW948 ( k, l ) and SW1222 ( m, n ) were tested using scBW431 / 26 -hFc protein ( filled ) (a, c, e, g, i, k, m). scPhOx -hFc protein was used as negative control for the scBW431 / 26 -hFc protein ( gray line ). For comparison, the FACS analysis using the mAb CEJ065 ( filled ) and an isotype control mAb ( gray line ) is shown (b, d, f, h, j, l, n).
Tumor targeting of a human NK cell line T Schirrmann and G Pecher YT cells was 94% 1 day after irradiation with 5000 rad, 37% 2 days after irradiation, 9% 4 days after irradiation, and < 2% 6 days after irradiation. To examine whether theirradiation influences the cytolytic properties of the scBW431/26-hFc gene -transfected YT we performed 51 Cr-release assays using these effector cells before and after -irradiation. Sixteen hours after -irradiation with 2000 -15000 rad scBW431 /26 -hFc -expressing YT cells lysed CEA + MC32A cells comparable to nonirradiated effector cells ( Fig 5i ) . Only scBW431 /26-hFc transgenic YT cells irradiated with 15,000 rad showed a slight decrease of cytolytic activity at lower E:T ratios. Irradiated (5000 rad ) scBW431/26-hFc -expressing YT cells lysed 23.4%
( E:T= 12.5:1 ) of the MC32A cells comparable to 23.6% lysis by nonirradiated effector cells (E:T= 12.5:1 ). Three days after irradiation with 5000 rad scBW431/26 -hFc transgenic YT cells lysed 7.5% of the MC32A cells and 5 days after irradiation, 1.5% ( E:T=12.5:1 ).
-Irradiated scBW431 / 26 -hFc -expressing YT cells inhibited CEA + tumor growth in a NOD / SCID mouse model
The in vivo efficacy of -irradiated cIgTCR transgenic YT cells was tested using a CEA + tumor model in NOD /SCID mice ( Fig 6 ) . The MC32A tumor growth was significantly inhibited in mice treated simultaneously with CEA transgenic MC32A tumor cells and 5000 -rad -irradiated YT cells expressing the scBW431 /26 -hFc receptor compared to mice treated with MC32A alone or together with 5000 -radirradiated scPhOx -hFc -expressing YT cells, respectively ( P <.05). Two mice of the group inoculated with MC32A cells and irradiated scBW431 /26 -hFc transgenic YT cells and one mouse of the group inoculated with MC32A cells alone did not develop any MC32A tumor during the observation time of 90 days.
Discussion
The generation of sufficient specific lymphocytes is a major requirement for an adoptive immunotherapy of tumor or viral diseases. Recently developed strategies to modify the specificity of T cells with recombinant T-cell receptors 9 -13 might overcome the prior limitations of lymphokineactivated killer cells ( LAK ) cells and TILs. 38, 39 However, the individual genetic modification of patients' effector cells might be problematic for routine clinical applications. Therefore, it would be helpful to employ an established effector cell line that is of unlimited availability and could be easily genetically modified.
The human NK cell line YT 23 possesses interesting properties because it grows cytokine-independent, mediates 
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Tumor targeting of a human NK cell line T Schirrmann and G Pecher potent cytotoxic activity against various NK sensitive cell lines, and can be transfected by electroporation without need of retroviral vector systems. In this study, we examined whether this NK cell line could be specifically targeted by gene transfer of a CEA -specific cIgTCR to CEA + colon carcinoma cell lines. The receptor construct scBW431 / 26-hFc consists of an scFv fragment derived from the humanized mAb BW431 /26, the hinge -CH2 -CH3 domains of human IgG1 heavy chain, and the transmembrane and cytoplasmatic part of the human CD3 signal chain. The extracellular part of the cIgTCR was expressed as scFv -hFc protein in 293T to analyze the specificity of the receptor and its antigen expression on colon carcinoma cell lines. This secretory mammalian expression system circumvents problems occurring with bacterial scFv expression systems and simplifies the analysis of the cIgTCR specificity. The scBW431 /26-hFc protein binds specifically to surface -attached CEA protein and to certain colon carcinoma cell lines.
The scBW431 / 26-hFc receptor gene was successfully transfected into the YT cell line by electroporation and the receptor-expressing cells could be enriched by immunoaffinity purification against the hFc part. The scBW431 / 26-hFc -expressing YT cells lyse specifically CEA + colon carcinoma cell lines, which were resistant against the parental YT cell line. The lysis correlates with the positive staining of the target cell lines using the scBW431 /26 -hFc protein.
Because soluble antigen could interfere with the cIgTCRmediated lysis, 2, 40 we examined the cytotoxicity of scBW431/26-hFc -expressing YT cells in the presence of soluble CEA protein. We did not find any inhibition of the tumor cell lysis by soluble CEA protein in concentrations up to 10 g /mL. This effect has been also demonstrated for T cells transduced with CEA - 11, 13 and TAG72 -specific cIgTCRs. 10 The mAb BW431 /26 has been shown to recognize specifically membrane -bound CEA and cannot be blocked by soluble CEA protein. 27, 41 Furthermore, the polyvalent interaction between cIgTCR -expressing effector cells and target cells should overrule the inhibitory effect of monomeric soluble antigens. 13 The clinical use of an allogeneic effector cell line would assume a strategy that employs a cell line not growing unlimited itself in patients. A method fulfilling this assumption would be -irradiation, which has been used for the MHC -nonrestricted T-cell line TALL -104 in patients with metastatic breast cancer in a phase I clinical trial. 42 
